Literature DB >> 11827459

Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts.

Long-Sheng Chang1, Elena M Akhmametyeva, Yong Wu, Lingyun Zhu, D Bradley Welling.   

Abstract

Northern blot analysis has shown that the human neurofibromatosis type 2 (NF2) cDNA hybridizes to multiple RNA species. To examine whether these hybridizing RNA species represent NF2 transcripts, we cloned the complete NF2 cDNA by a combination of techniques: 5' and 3' rapid amplification of cDNA ends, RT-PCR, and searching and sequencing the NF2-related cDNA clones from the IMAGE consortium. We showed that human NF2 transcripts initiate at multiple positions. Analogous to those reported previously, NF2 transcripts undergo alternative splicing in the coding exons. We isolated eight alternatively spliced NF2 cDNA isoforms, including one that contains a new exon termed exon 2', which potentially could encode proteins of different sizes. We assembled the overlapping cDNA fragments, and the longest NF2 cDNA, containing all 17 exons, consists of 6067 nucleotides, which is consistent with the size of the major RNA species hybridized to the NF2 probe. The cDNA has a 425-nucleotide 5' untranslated region upstream from the ATG start codon, and a long 3' untranslated region of 3869 nucleotides. We also isolated two shorter NF2 cDNAs that were terminated by different polyadenylation signal sequences, which indicates that differential usage of multiple polyadenylation sites also contributes to the complexity of human NF2 transcripts. By reference to the transcription initiation site mapped, we analyzed the 5' flanking sequence of the human NF2 gene. Transient transfection analysis in human 293 kidney, SK-N-AS neuroblastoma, and NT2/D1 teratocarcinoma cells with NF2 promoter-luciferase chimeric constructs revealed a core promoter region extending 400 base pairs from the major transcription initiation site. Although multiple regions are required for full promoter activity, a site-directed mutagenesis experiment identified a GC-rich sequence (position -58 to -46), which could be bound by transcription factor Sp1, as a positive cis-acting regulatory element. Cotransfection studies in Drosophila melanogaster SL2 cells showed that Sp1 could activate the NF2 promoter through the GC-rich sequence.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11827459     DOI: 10.1006/geno.2001.6672

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  13 in total

Review 1.  Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival.

Authors:  Ivan Stamenkovic; Qin Yu
Journal:  Curr Protein Pept Sci       Date:  2010-09       Impact factor: 3.272

2.  AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.

Authors:  Matthew L Bush; Janet Oblinger; Victoria Brendel; Griffin Santarelli; Jie Huang; Elena M Akhmametyeva; Sarah S Burns; Justin Wheeler; Jeremy Davis; Charles W Yates; Abhik R Chaudhury; Samuel Kulp; Ching-Shih Chen; Long-Sheng Chang; D Bradley Welling; Abraham Jacob
Journal:  Neuro Oncol       Date:  2011-07-21       Impact factor: 12.300

3.  A novel alternative splicing isoform of NF2 identified in human Schwann cells.

Authors:  Fang Su; Zhengguang Zhou; Wen Su; Zishu Wang; Qiong Wu
Journal:  Oncol Lett       Date:  2016-06-08       Impact factor: 2.967

4.  Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.

Authors:  Sarah S Burns; Elena M Akhmametyeva; Janet L Oblinger; Matthew L Bush; Jie Huang; Volker Senner; Ching-Shih Chen; Abraham Jacob; D Bradley Welling; Long-Sheng Chang
Journal:  Cancer Res       Date:  2012-11-14       Impact factor: 12.701

5.  Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.

Authors:  Tina X Lee; Mark D Packer; Jie Huang; Elena M Akhmametyeva; Samuel K Kulp; Ching-Shih Chen; Marco Giovannini; Abraham Jacob; D Bradley Welling; Long-Sheng Chang
Journal:  Eur J Cancer       Date:  2009-04-07       Impact factor: 9.162

6.  The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion.

Authors:  Margaret E McLaughlin; Genevieve M Kruger; Kelly L Slocum; Denise Crowley; Norman A Michaud; Jennifer Huang; Margaret Magendantz; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

7.  Strong conservation of the human NF2 locus based on sequence comparison in five species.

Authors:  Caisa M Hansson; Haider Ali; Carl E G Bruder; Ingegerd Fransson; Sindy Kluge; Björn Andersson; Bruce A Roe; Uwe Menzel; Jan P Dumanski
Journal:  Mamm Genome       Date:  2003-08       Impact factor: 2.957

8.  Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity.

Authors:  Pierig Lepont; John T Stickney; Lauren A Foster; Jin-Jun Meng; Robert F Hennigan; Wallace Ip
Journal:  Mutat Res       Date:  2007-08-06       Impact factor: 2.433

9.  The molecular biology of vestibular schwannomas and its association with hearing loss: a review.

Authors:  Erika Celis-Aguilar; Luis Lassaletta; Miguel Torres-Martín; F Yuri Rodrigues; Manuel Nistal; Javier S Castresana; Javier Gavilan; Juan A Rey
Journal:  Genet Res Int       Date:  2012-02-20

Review 10.  Genomics, Epigenetics, and Hearing Loss in Neurofibromatosis Type 2.

Authors:  Christine T Dinh; Eric Nisenbaum; Darius Chyou; Carly Misztal; Denise Yan; Rahul Mittal; Juan Young; Mustafa Tekin; Fred Telischi; Cristina Fernandez-Valle; Xue-Zhong Liu
Journal:  Otol Neurotol       Date:  2020-06       Impact factor: 2.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.